CMO revenue expected to double in Europe in 6 years

As patents for key blockbuster drugs begin to expire and plant use begins to wane, experts are looking to Europe for a boom in contract manufacturing. According to consultancy firm Frost & Sullivan, CMO revenue on the Continent should double over the next 6 years, with pharma outsourcing expected to reach $20.75 billion, up from $10.02 billion last year. Of course, as that trend continues to grow, so can risks--like drug contamination, recalls and safety issues--which should result tighter rules and regulations, and that can put pressure on CMOs, according to the Frost & Sullivan analysts. More details can be found in Eric Palmer's story on FiercePharmaManufacturing. More

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.